Form D · Pharmaceuticals
Chrysalis Biotherapeutics, Inc.
Galveston, TX · CIK 0002016438
Offering snapshot reported Mar 22, 2024 · SEC filing
- Reported sold
- $515K Offering amount: $3M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Nov 28, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 22, 2024 | Initial | $515,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-508350
Source: Form D, filed Mar 22, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Darrell Carney | Director, Executive |
| Marie Robb | Director |
| James Ryaby | Director |
| Timothy Schmidt | Director |
| Jeffery Sheldon | Director |
| Lauri Sower | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2200 Market St, Suite 606
Galveston, TX, 77550
Galveston, TX, 77550